Format

Send to

Choose Destination
Malar J. 2017 Aug 17;16(1):343. doi: 10.1186/s12936-017-1976-8.

A new method for sequencing the hypervariable Plasmodium falciparum gene var2csa from clinical samples.

Author information

1
Division of Malaria Research, Institute for Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
2
Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA.
3
Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA. jcsilva@som.umaryland.edu.
4
Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, USA. jcsilva@som.umaryland.edu.

Abstract

BACKGROUND:

VAR2CSA, a member of the Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) family, mediates the binding of P. falciparum-infected erythrocytes to chondroitin sulfate A, a surface-associated molecule expressed in placental cells, and plays a central role in the pathogenesis of placental malaria. VAR2CSA is a target of naturally acquired immunity and, as such, is a leading vaccine candidate against placental malaria. This protein is very polymorphic and technically challenging to sequence. Published var2csa sequences, mostly limited to specific domains, have been generated through the sequencing of cloned PCR amplicons using capillary electrophoresis, a method that is both time consuming and costly, and that performs poorly when applied to clinical samples that are commonly polyclonal. A next-generation sequencing platform, Pacific Biosciences (PacBio), offers an alternative approach to overcome these issues.

METHODS:

PCR primers were designed that target a 5 kb segment in the 5' end of var2csa and the resulting amplicons were sequenced using PacBio sequencing. The primers were optimized using two laboratory strains and were validated on DNA from 43 clinical samples, extracted from dried blood spots on filter paper or from cryopreserved P. falciparum-infected erythrocytes. Sequence reads were assembled using the SMRT-analysis ConsensusTools module.

RESULTS:

Here, a PacBio sequencing-based approach for recovering a segment encoding the majority of VAR2CSA's extracellular region is described; this segment includes the totality of the first four domains in the 5' end of var2csa (~5 kb), from clinical malaria samples. The feasibility of the method is demonstrated, showing a high success rate from cryopreserved samples and more limited success from dried blood spots stored at room temperature, and characterized the genetic variation of the var2csa locus.

CONCLUSIONS:

This method will facilitate a detailed analysis of var2csa genetic variation and can be adapted to sequence other hypervariable P. falciparum genes.

KEYWORDS:

Malaria; PacBio; Sequencing; Vaccines; var2csa

PMID:
28818101
PMCID:
PMC5561619
DOI:
10.1186/s12936-017-1976-8
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center